10:07 AM Zacks Investment Research
The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study. [Read More]
Sarepta Therapeutics Inc. undefined shares plummeted as much as 20% in after-hours trading Thursday, after the company reported that a study had been put on... [Read More]
Sarepta Therapeutics Inc. SRPT, +5.14% ... [Read More]
Thursday, June 23 - 4:01 PM The Street
Sarepta Therapeutics, Inc. SRPT, the leader... [Read More]
Check out the stocks making notable moves after the bell on Thursday, June 23. [Read More]
Popular Tags
Hot Topics
- #1 President Joe Biden
- #2 Title IX
- #3 Donald Trump
- #4 Federal Reserve
- #5 NBA Draft
- #6 Drug Administration
- #7 Pride Month
- #8 Planned Parenthood
- #9 World Cup
- #10 European Union
- #11 Roe V Wade
- #12 Disease Control
- #13 Independence Day
- #14 Uvalde Texas
- #15 Elon Musk
- #16 Second Amendment
- #17 Father's Day
- #18 Stanley Cup
- #19 Tampa Bay
- #20 Paolo Banchero
- #21 Washington AP
- #22 College World Series
- #23 Colorado Avalanche
- #24 Baz Luhrmann
- #25 Golden State
- #26 Yellowstone National Park
- #27 United States Supreme Court
- #28 Stranger Things
- #29 American Rescue Plan
- #30 Orlando Magic
- #31 Vice President Mike
- #32 American Legion
- #33 Westminster Kennel Club
- #34 Austin Butler
- #35 Anita Alvarez
- #36 Elvis Presley
- #37 Supreme Court Justice
- #38 World Health Organization
- #39 Human Services
- #40 North Korea
- #41 Watch Now
- #42 Robb Elementary School
- #43 Jeffrey Clark
- #44 Arch Manning
- #45 PGA Tour
- #46 Obituaries for June 24
- #47 President Trump
- #48 Johnny Depp
- #49 Amber Heard
- #50 Liv Golf
